| This week's sponsor is CMIC Group. | | | Considering Japanese Market Entry?
As Japan's largest CRO with end-to-end solution, CMIC Group is your most experienced partner in Japan & the US. Our experts will help you determine the best strategy at any stage of drug development.
Click here to learn more! |
Today's Rundown Blackstone, Novartis found cardiovascular startup with $250M Sarepta pulls the trigger on $165M Myonexus buy Servier terminates CTI cancer pact following clinical failure [Sponsored] Rise in Targeted Therapies Drives Need for Flexible, Small-Volume Manufacturing CytomX slumps as BMS bails on 3 partnered projects Sellas mulling ‘strategic options’ to stay afloat, including sale Parexel, on a hiring spree, nabs another key FDA staffer as it bolsters oncology executives Featured Story | | | Wednesday, February 27, 2019 Blackstone Life Sciences has committed $250 million to create a cardiovascular startup with Novartis. The biotech, Anthos Therapeutics, begins life with an anti-factor XI antibody that Novartis took to the cusp of phase 2 as an antithrombotic therapy. |
|
|
| This week's sponsor is Sprout BioVentures. | | | Final Week for Golden Sprout Competition
Don’t miss out on 6 months of chemistry support at no cost. Strengthen your chemical starting points and work with a world-class research organization trusted by global biopharma. Click here to download the application. |
Top Stories Wednesday, February 27, 2019 Sarepta expanded into limb-girdle muscular dystrophy last May, when it ponied up $60 million to license five gene therapies and snag an option to acquire the French company. Now, it's buying Myonexus and its pipeline outright for $165 million. Wednesday, February 27, 2019 Servier has terminated its Pixuvri collaboration agreement with CTI BioPharma. The action comes seven months after the B-cell non-Hodgkin lymphoma drug failed a key clinical trial. Monday, February 25, 2019 Biologics have experienced steady double-digit growth over the last 15 years and now comprise slightly more than a quarter of all New Molecular Entity (NME) FDA approvals. Wednesday, February 27, 2019 Amid an R&D update from CytomX is the news that partner Bristol-Myers Squibb has dropped three programs, putting pressure on the biotech's share price. Wednesday, February 27, 2019 Sellas Life Sciences is considering a number of “strategic options” to make sure it can fund its current plan of developing its leading oncology assets, a pair of cancer vaccines. Wednesday, February 27, 2019 Not content with hiring four former FDA staffers this month, Parexel is at it again, nabbing another top ex-FDA executive and promoting a former medical oncologist to boost its cancer drug development services. Resources Sponsored by: ON24 Which HCP Touchpoints and channels are yielding the best results in today’s digital world? Sponsored by: Blue Matter White paper outlining the key types of cell-based immunotherapies in oncology, as well as the development and commercial outlook for each. Sponsored by: AlphaSense It’s never been more challenging to stay on top of trends and innovation shaping the future of healthcare. Discover how AI can help competitive intelligence teams achieve more proactive strategies. Sponsored by: Patheon, part of Thermo Fisher Scientific When a biologics company prepares to launch a new product, it must forecast the manufacturing capacity it will need, factoring in its estimate of the size of future sales, the timing of the launch, the dosage of the product, its strategy for building its market and a host of other variables. Sponsored by: Oracle Health Sciences 92% of survey respondents make changes to their RTSM/IRT systems due to study changes. See what else puts a strain on their clinical trials. Download the Research Whitepaper. Sponsored by: Patheon, part of Thermo Fisher Scientific Download this whitepaper to learn more. Sponsored by: The Kinetix Group Explore how the pharma industry can adapt its approach to the changing healthcare marketplace in the era of the Quadruple Aim Sponsored by: Cofactor Genomics Learn how Health Expression Models provide increased sensitivity, specificity, and accuracy for characterizing immune response in solid tumor specimens. Sponsored by: BioAnalytix, Inc. This whitepaper reviews fundamental aspects of HCPs that pertain to biologic drug development and presents current and emerging approaches to HCP analysis. Sponsored by: Veradigm Clinical trials take too long and cost too much—here's what needs to change. Sponsored by: Outer Edge Technology With FDA approval imminent, start-up Life Sciences company partners with an industry focused MSP to design and manage its regulated cloud-based infrastructure to speed time to market. Presented by: Veeva Share your thoughts on the life sciences industry's progress in improving study execution. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. BIO Asia International Conference March 5-6, 2019 | Grand Hyatt Tokyo | Tokyo, Japan BioBasics: Biotech For The Non-Scientist March 28-29, 2019 | Boston, MA Drug Development Immersion April 3-4, 2019 | Philadelphia, PA PEGS: The Essential Protein Engineering Summit April 8 – 12, 2019 | Boston, MA Middle East Life Sciences Compliance Training April 29, 2019 – May 2, 2019 | Dubai U.A.E. 2019 BIO International Convention June 3-6, 2019 | Philadelphia, PA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! | 